When taking a medicine off the shelves infringes competition law
At a time when industry experts are talking about the death of the blockbuster drug, product lifecycle management strategies are taking centre stage.
Natasha Kirk and Stephen Whitfield discuss two recent cases in an article for Regulatory Affairs Pharma which show that competition regulators in the EU are prepared to investigate and punish companies that engage in practices that extend beyond legitimate product lifecycle management and into an abuse of a dominant market position.
Download the article (subscription only)
Lawyers
